Trials / Completed
CompletedNCT01931761
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
A Phase I, Single-centre, Non-randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-Selumetinib in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 50 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the absorption, distribution, metabolism and excretion (ADME) of single dose \[14C\] selumetinib in volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [C14] selumetinib (oral) | Single oral administration \[C14\] 75mg |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2013-08-29
- Last updated
- 2015-06-30
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01931761. Inclusion in this directory is not an endorsement.